ライフサイエンスコーパス: AA amyloidosis

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 entire cohort was 19 years from diagnosis of AA amyloidosis.

2 k in our understanding of the development of AA amyloidosis.

3 us findings that short HS fragments preclude AA amyloidosis.

4 ss the initial events in the pathogenesis of AA amyloidosis.

5 e an explanation for the lysosomal origin of AA amyloidosis.

6 isate slows the decline of renal function in AA amyloidosis.

7 ized chiefly by arthralgia, skin rashes, and AA amyloidosis.

8 is review summarizes current knowledge about AA amyloidosis.

9 the inflammation-related disease amyloid A (AA) amyloidosis.

10 ved to play a role in the disease Amyloid A (AA) Amyloidosis.

11 A) has been linked to the disease amyloid A (AA) amyloidosis.

12 se or systemic light chain (AL) or reactive (AA) amyloidosis.

13 SAF-1 plays a key role in the development of AA amyloidosis, a consequence of chronic inflammation.

14 iple organs resulting in reactive amyloid A (AA) amyloidosis, a consequence of rheumatoid arthritis,

15 cy and safety of eprodisate in patients with AA amyloidosis and kidney involvement.

16 igns of inflammation and a long-term risk of AA amyloidosis and overt lymphoproliferation.

17 es, fever, arthralgia, and in some subjects, AA amyloidosis, and have been mapped to chromosome 1q44.

18 -overexpressing mice spontaneously developed AA amyloidosis at the age of 14 mo or older.

19 AA amyloidosis can be induced in mice experimentally thr

20 Therefore, AA amyloidosis can be thought of as a consequence of lon

21 the rapid onset of renal failure in clinical AA amyloidosis following acute exacerbation of inflammat

22 However, its role in the pathogenesis of AA amyloidosis has thus far remained obscure.

23 nally, observations from a clinical trial in AA amyloidosis have generated hypotheses about the relat

24 t been considered prior to presentation with AA amyloidosis in 23 patients (50%).

25 ble of selectively imaging systemic visceral AA amyloidosis in a murine model of the disease.

26 We report 2 further cases of patients with AA amyloidosis in HIDS, both of whom developed dialysis-

27 F-1 transgenic mice rapidly developed severe AA amyloidosis in response to azocasein injection, indic

28 r 12-117 months in 80 patients with systemic AA amyloidosis in whom serum SAA concentration was measu

29 AA amyloidosis is a life-threatening complication of the

30 AA amyloidosis is the most serious potential complicatio

31 Clinical AA amyloidosis is typically preceded by many years of ac

32 Amyloid A (AA) amyloidosis is a complication of chronic inflammator

33 Systemic amyloid A (AA) amyloidosis is a serious complication of chronic inf

34 Inflammation-related (AA) amyloidosis is a severe clinical disorder characteri

35 e SAF family, is abundantly present in human AA amyloidosis patients.

36 of this unique in vivo experimental model of AA amyloidosis provides the means to assess the therapeu

37 Clinical AA amyloidosis rarely involves the heart, but amyloidoti

38 AA amyloidosis remains a challenging and serious late co

39 es of 20 patients with FMF and biopsy-proven AA amyloidosis that were transplanted between 1995 and 2

40 In AA amyloidosis, the expression of cytokines, particularl

41 SAA is a protein precursor of reactive AA amyloidosis, the major complication of chronic inflam

42 an time to progression to ESRF from onset of AA amyloidosis was 3.3 years (interquartile range [IQR]

43 was 5 years; median age at presentation with AA amyloidosis was 38 years.

44 Recurrence of AA amyloidosis was diagnosed in 2 patients during the fi

45 -1 is directly linked to the pathogenesis of AA amyloidosis, we have developed a SAF-1 transgenic mou

46 Using a murine model of AA amyloidosis, we have examined the in vivo amyloid rea

47 namic turnover, and outcome is favourable in AA amyloidosis when the SAA concentration is maintained

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。